NEW YORK, July 18, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Exelixis, Inc. (NASDAQ: EXEL), InterMune Inc. (NASDAQ: ITMN), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4874-100free.
Questcor Pharmaceuticals, Inc. Analyst Notes
On July 14, 2014, Questcor Pharmaceuticals Inc. (Questcor) and Mallinckrodt plc (Mallinckrodt) announced that the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission by Mallinckrodt was declared effective on July 11, 2014. Both companies also announced their plans to hold their respective shareholder meetings on August 14, 2014, for shareholders of record on July 9, 2014. The meeting's discussion will cover: Mallinckrodt's proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor, and in the case of Questcor, the approval of the merger agreement with Mallinckrodt and related matters. The Company added that the transaction is currently expected to be completed in August 2014. The full analyst notes on Questcor are available to download free of charge at:
http://www.analystsreview.com/Jul-18-2014/QCOR/report.pdf
Exelixis, Inc. Analyst Notes
On July 14, 2014, Exelixis, Inc. (Exelixis) announced positive top-line results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring the BRAFV600 mutation. Results showed that the study met its primary endpoint, delivering a statistically significant increase in progression-free survival (PFS) for the combination of cobimetinib plus vemurafenib as compared to vemurafenib alone. "These positive top-line results from coBRIM represent an important milestone for melanoma patients and their physicians, and are the first of four anticipated phase 3 pivotal trial read-outs for Exelixis-discovered compounds in 2014," said Michael M. Morrissey, Ph.D., President and CEO of Exelixis. Exelixis stated that its collaborator Genentech, a member of the Roche Group, will present these coBRIM data at an upcoming medical meeting and plans to initiate regulatory filings before year end. The full analyst notes on Exelixis are available to download free of charge at:
http://www.analystsreview.com/Jul-18-2014/EXEL/report.pdf
InterMune Inc. Analyst Notes
On July 16, 2014, InterMune Inc.'s (InterMune) stock dipped 2.97% to end the day at $41.56 compared to the previous day's closing price of $42.83. The Company's stock rose 46.79% over the past three trading months compared to the Nasdaq Composite which rose 8.31% during the same trading period. The full analyst notes on InterMune are available to download free of charge at:
http://www.analystsreview.com/Jul-18-2014/ITMN/report.pdf
Progenics Pharmaceuticals Inc. Analyst Notes
On July 14, 2014, Progenics Pharmaceuticals Inc. (Progenics) and Salix Pharmaceuticals, Ltd. (Salix) announced that Salix has been informed by the Food and Drug Administration (FDA) that RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain can be approved on the data submitted in the sNDA. FDA has directed Salix to work with and submit certain information to the Division of Gastroenterology and Inborn Errors Products (DGIEP), which Salix intends to submit the over the next several weeks. "The approval and availability of RELISTOR for this expanded use will be an important and welcomed advancement for treating the underlying cause of OIC experienced by many patients taking opioids for chronic non-cancer pain," stated Bill Forbes, Executive Vice President, Medical, Research and Development and Chief Development Officer, Salix. The full analyst notes on Progenics are available to download free of charge at:
http://www.analystsreview.com/Jul-18-2014/PGNX/report.pdf
Arrowhead Research Corp. Analyst Notes
On July 16, 2014, Arrowhead Research Corp.'s (Arrowhead) stock declined 2.70% to end the day at $11.87 compared to the previous day's closing price of $12.20. The Company's stock lost 3.89% over the past three trading days compared to the Nasdaq Composite which rose 0.24% during the same trading period. The full analyst notes on Arrowhead are available to download free of charge at:
http://www.analystsreview.com/Jul-18-2014/ARWR/report.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.analystsreview.com
SOURCE Analysts Review
